TNSALP Inhibitors
1 drugsAbout TNSALP
Tissue Non-Specific Alkaline Phosphatase (TNSALP) is an enzyme involved in bone mineralization and phosphate metabolism.
Currently, there is no genetic evidence directly linking TNSALP to specific diseases, but its role in bone mineralization makes it a therapeutic target.
TNSALP is targeted by one FDA-approved biologic drug, STRENSIQ, developed by Alexion Pharmaceuticals for a specific set of conditions.
Top TNSALP Drugs
Alexion Pharmaceuticals is the only company with an approved drug targeting TNSALP.
The market is highly concentrated, indicating potential entry barriers or limited competition.
TNSALP Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TNSALP, using enzyme modality.
Explore alternative modalities like small molecules to differentiate from existing therapies.
TNSALP Clinical Trials 12 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TNSALP. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 7 | 7 | 0 | 0 | 100% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
| Phase 4 | 2 | 1 | 1 | 0 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TNSALP Drug Approval Timeline (2015 - 2015)
The first and only drug, STRENSIQ, was approved in 2015.
The approval timeline shows no recent activity, suggesting a saturated market or challenges in developing new TNSALP-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TNSALP. A trial counts if an approved drug acting on TNSALP is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.